Start-up pitch
The start-up pitch session is supported by INCATE and partners from the AMR community. Eleven finalists were selected that will have the opportunity to make a 5-minute-pitch of their venture in the start-up pitch session on 6 March. The best pitch will win a 10,000 € prize from award sponsor Vossius, one of the leading IP law firms in Europe.
Proudly presenting the finalists:
Till Schäberle
BamA Inhibitors
We will develop the first in class BamA inhibitor against MDR Gram-negative ESKAPE pathogens.
Stuart Hannah
Microplate Dx
The Microplate Dx rapid AST technology enables clinicians to choose the right antibiotic for patients in minutes at the point of care, much quicker than gold-standard lab based techniques.
Johan Wikstrom
Tolka AI
Phage-therapy-as-a-service platform against nontuberculous mycobacteria.
Guillaume Vandenesch
Generare
Generare is a tech bio platform discovering novel natural products at scale tofight AMR.
Baris Ata Borsa
Theralia
TOUCAN Technology, as a unique oligonucleotide-based drug development platform, enables of using many potent but also toxic antimicrobial molecules, such as nucleoside analogues, safely in the treatment of infectious diseases by limiting their systemic side effects via precise delivery to the area of infection
Martin Duffner
Puray
Utilizing UV light, Puray provides the world’s first permanent sterile medical tubing, offering superior infection prevention for patients.
Robert Macsics
smartbax
smartbax is developing small-molecule antibiotics with novel modes of action and a particular focus on enzyme activation instead of inhibition.